SCHEMBL7904233

SCHEMBL7904233

CC1=NC(C)CNc2c1cccc2[N+](=O)[O-]

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 3/20 0.41
KLK3 P07288 1/20 0.38
TSHR P16473 3/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MGAM O43451 1/20 0.38
GAA P10253 1/20 0.38
SI P14410 1/20 0.38
MGAM2 Q2M2H8 1/20 0.38
S100A4 P26447 1/20 0.37
MAPT P10636 2/20 0.37
RECQL P46063 1/20 0.37
KMT2A Q03164 1/20 0.37
MCL1 Q07820 1/20 0.37
RXFP1 Q9HBX9 1/20 0.37
HSD17B10 Q99714 1/20 0.37
MAPK1 P28482 2/20 0.36
POLB P06746 1/20 0.36
ALDH1A1 P00352 3/20 0.35
NPC1 O15118 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6196688 0.75 TSHR (0.41) TDP1TSHRSMN1; SMN2S100A4MAPT
SCHEMBL6196680 0.75 TSHR (0.41) TDP1TSHRSMN1; SMN2S100A4MAPT
SCHEMBL6200104 0.75 TSHR (0.41) TDP1TSHRSMN1; SMN2S100A4MAPT
SCHEMBL8588673 0.71 S100A4 (0.42) TDP1SMN1; SMN2GAAS100A4MAPT
SCHEMBL31297473 0.69 S100A4 (0.41) TDP1TSHRSMN1; SMN2S100A4MAPT
SCHEMBL8588432 0.69 S100A4 (0.40) TDP1TSHRSMN1; SMN2GAAS100A4
SCHEMBL7903563 0.68 TDP1 (0.39) TDP1TSHRSMN1; SMN2GAAMAPT
SCHEMBL9539807 0.68 PNMT (0.43) TDP1TSHRSMN1; SMN2HSD17B10POLB
SCHEMBL9539813 0.68 PNMT (0.43) TDP1TSHRSMN1; SMN2HSD17B10POLB
SCHEMBL7903560 0.68 TDP1 (0.39) TDP1TSHRSMN1; SMN2GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6201119-B1 2,3,4,5-TETRAHYDRO-1H-1,4-BENZODIAZEPIN-9-AMINE COMPOUNDS USEFUL AS INTERMEDIATES TO ANTIVIRALS JANSSEN PHARMACEUTICA N.V. (BE) 2001-03-13 US disclosed
CN-1029971-C Process for preparating antiviral tetrahydroimidazo (1,4) benzodiazepines JANSSEN PHARMACEUTICA NV (BE) 1995-10-11 CN disclosed
EP-0417840-B1 Antiviral tetrahydroimidazo [1,4]-benzodiazepines JANSSEN PHARMACEUTICA NV (BE) 1994-12-07 EP disclosed
US-5371079-A Administering to inhibit replication of HIV-1 in human cells JANSSEN PHARMACEUTICA N.V. (BE) 1994-12-06 US disclosed
US-5270464-A Anti-HIV-1 tetrahydroimidazo[1,4]benzodiazepin-2-(thi) ones JANSSEN PHARMACEUTICA N.V. (BE) 1993-12-14 US disclosed
EP-0491751-A1 ANTIVIRAL TETRAHYDROIMIDAZO 1,4]BENZODIAZEPINES JANSSEN PHARMACEUTICA N.V. (BE) 1992-07-01 EP disclosed
WO-1991004255-A1 ANTIVIRAL TETRAHYDROIMIDAZO[1,4]BENZODIAZEPINES JANSSEN PHARMACEUTICA N.V. (BE) 1991-04-04 WO disclosed
CN-1050192-A Prepare the also method of [1,4] benzodiazepine of antiviral imidazolidine JANSSEN PHARMACEUTICA NV (BE) 1991-03-27 CN disclosed